Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351841 | 0.87 | MTNR1A (0.34) | MTNR1AELANENPSR1KMT2A | |
| SCHEMBL5341913 | 0.87 | CYP3A4 (0.39) | KMT2A | |
| SCHEMBL5346149 | 0.86 | MTNR1A (0.36) | MTNR1AELANENPSR1KMT2A | |
| SCHEMBL6076964 | 0.81 | MCL1 (0.34) | MTNR1AKMT2A | |
| SCHEMBL5338376 | 0.75 | CYP2C19 (0.43) | KMT2A | |
| SCHEMBL6077217 | 0.74 | CYP2C19 (0.42) | MTNR1AKMT2A | |
| SCHEMBL5346060 | 0.69 | TRPV1 (0.36) | KMT2A | |
| SCHEMBL5336707 | 0.68 | ALOX5 (0.44) | MTNR1ANR3C1 | |
| SCHEMBL21154620 | 0.63 | MTNR1A (0.39) | MTNR1AELANENPSR1KMT2A | |
| SCHEMBL9764484 | 0.60 | NPSR1 (0.49) | NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885ELANE 2074/4885NPSR1 368/4885 |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885ELANE 2660/4885NPSR1 592/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885ELANE 2074/4885NPSR1 368/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | MTNR1A 409/4885ELANE 2765/4885NPSR1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.